Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how circulating tumor DNA (ctDNA) can help doctors understand how well neoadjuvant therapy (treatment given before surgery) is working for patients with stage I-III breast cancer. ctDNA is a small piece of genetic material that comes from cancer cells and can be found in the blood. By monitoring ctDNA levels, researchers hope to see if it can be used as a reliable marker to track the response to treatment.

To be eligible for this study, participants must be at least 18 years old and diagnosed with stage I-III invasive breast cancer, and they should not have received any previous cancer treatment. The trial is open to all genders. Participants will have regular blood tests to check their ctDNA levels, and they will be monitored throughout the study to see how their cancer responds to the treatment. It’s important to note that some health conditions, like serious infections or other major diseases, may prevent someone from joining the trial. This study is currently recruiting, and it aims to provide valuable information that could improve treatment approaches for breast cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient is ≥ 18 years-old at the time of consent to participate this trial
• • Patients with stage I-III invasive breast cancer
• • No prior anti-cancer treatment
• • Felt to be a possible candidate for neoadjuvant therapy by their physician
• Exclusion Criteria:
• • Known to have other aggressive malignant tumor in the past 5 years.
• • Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators.
• • There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.
• • The investigator determines that subjects are not appropriate to participate in the study due to other factors.